APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentRevenue01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentRevenue02Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:FourReportableSegmentRevenue01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:FourReportableSegmentRevenue02Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentResults01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentResults02Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:FourReportableSegmentResults01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:FourReportableSegmentResults02Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentAssets01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentAssets02Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentLiabilities01Member APOLLOHOSP2019-12-31in-bse-fin:OneReportableSegmentLiabilities01Member APOLLOHOSP2019-10-012019-12-31in-bse-fin:OneReportableSegmentLiabilities02Member APOLLOHOSP2019-12-31in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares APOLLOHOSP 2019-04-01 2020-03-31 2019-12-27 INR Lakhs Third quarter Multi segment 2019-10-01 2019-12-31 Unaudited Standalone 25295000000.00 30100000.00 25325100000.00 3976000000.00 9685000000.00 -344000000.00 3924400000.00 1109800000.00 1230800000.00 4286700000.00 23868700000.00 1456400000.00 0.00 1456400000.00 572800000.00 -63900000.00 508900000.00 0.00 947500000.00 0.00 0.00 0.00 947500000.00 -8000000.00 939500000.00 947500000.00 939500000.00 695600000.00 5 6.81 6.81 0.00 0.00 6.81 6.81 The unaudited standalone financial results of Apollo Hospitals Enterprise Limited for the three months and nine months ended December 31, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 12, 2020 and February 13, 2020 respectively and have been subjected to limited review by the statutory auditors.The Board of Directors in their meeting held on February 13, 2020 have declared an interim dividend @65% i.e., Rs.3.25 (Rupees Three and Twenty Five paise} per equity share of Rs.5 (Rupees Five only) each, for the financial year ending¿ March 31, 2020. The Company has fixed Wednesday, February 26, 2020 as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before March 5, 2020.The listed non-convertible debentures of the Company aggregating to¿ Rs. 50,000 lakhs as on December 31, 2019 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.¿The Board of Directors at their meeting held on November 14, 2018 had approved a Scheme of Arrangement (¿the Scheme¿) between Apollo Hospitals Enterprise Limited (¿AHEL¿) and Apollo Pharmacies Limited (¿APL¿) and their respective shareholders¿ for the transfer of the front-end retail pharmacy business carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, National Company Law Tribunal and all other requisite regulatory authorities.¿¿The Company received no objection letters from National Stock Exchange of India Limited and BSE Limited. Further, the Company obtained approvals from Competition Commission of India (CCI) and from the equity shareholders in October 2019. The Scheme would become effective upon filing of the Scheme, as sanctioned by the NCLT, with the Registrar of Companies. Multi segment 2019-04-01 2019-12-31 Unaudited Standalone 72222800000.00 116900000.00 72339700000.00 11603200000.00 27198400000.00 -937500000.00 11262200000.00 3185900000.00 3532100000.00 12427400000.00 68271700000.00 4068000000.00 0.00 4068000000.00 1727000000.00 -305500000.00 1421500000.00 0.00 2646500000.00 0.00 0.00 0.00 2646500000.00 2400000.00 2648900000.00 2646500000.00 2648900000.00 695600000.00 5 19.02 19.02 0.00 0.00 19.02 19.02 1.¿ ¿The Board of Directors of the Company had approved the sale of investments in an associate, Apollo Munich Health Insurance Company Limited (AMHI) to Housing Development Finance Corporation Limited subject to meeting closing conditions, which includes obtaining regulatory approvals from Insurance Regulatory and Development Authority of India (IRDA), Competition Commission of India (CCI) and National Housing Bank (NHB).The approval from IRDA was received on January 1, 2020 and the closing conditions were met on January 9, 2020.The Board of Directors in their meeting held on February 13, 2020, approved the proposal of merger of following subsidiary companies with the Company.a.¿¿¿ Apollo Home Healthcare (India) Limited and¿b.¿¿¿ Western¿ Hospitals Corporation Private LimitedEffective April 1, 2019, the Company adopted Ind AS 116 Leases , applied to all leasecontracts existing as on the said date, using the modified retrospective method. Under this method, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019. ¿¿On transition to Ind AS 116, the Company recognised right-of-use assets amounting to Rs. 120,539 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 141,926 lakhs and Rs. 24,193 lakhs (debit) in retained earnings (net of deferred tax) as at April 1, 2019. The Company has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability.During the three and nine months ended December 31, 2019, the Company has recognized interest expense on lease liabilities amounting to Rs. 3,224 lakhs & ¿¿¿¿Rs. 9,449 lakhs and depreciation on right-of-use asset amounting to Rs. 3,914 lakhs and Rs. 11,158 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs.1,415 lakhs and Rs.4,085 lakhs for the three and nine months ended December 31, 2019, respectively. Other Expenditure 4286700000.00 Other Expenditure 12427400000.00 Healthcare services 12971200000.00 pharmacy 12326100000.00 Healthcare services 37608900000.00 pharmacy 34621100000.00 2300000.00 7200000.00 25295000000.00 72222800000.00 Healthcare services 1784200000.00 pharmacy 751900000.00 Healthcare services 5092900000.00 pharmacy 2044100000.00 1109800000.00 3185900000.00 -30100000.00 -116900000.00 1456400000.00 4068000000.00 Healthcare services 68740400000.00 pharmacy 19424000000.00 13984000000.00 Healthcare services 15421700000.00 pharmacy 10457800000.00 38215100000.00